China Life Insurance

China Life Insurance is a Beijing-based state-affiliated institutional investor that deploys monumental capital pools across Chinese real economy sectors, including healthcare services and tech-enabled care infrastructure. The healthcare investment posture sits inside a broader insurance and asset management mandate rather than a standalone venture or growth fund, with focus areas spanning care delivery and digital health platforms. There is no marketed artificial intelligence thesis. Limited public information is available about individually named investment partners attached to specific healthcare deals or a clearly delineated public healthcare portfolio at the sub-vertical level.

The firm engages at Series C and growth stages with check sizes typically of twenty-five million dollars or more, often deployed through subsidiary asset management structures or as a limited partner in dedicated funds. Geographic concentration is China, with selective international exposure consistent with the priorities of a Chinese state-affiliated investor. Capital is highly patient and tied to long-term policy and demographic themes, including aging populations and the modernization of healthcare delivery infrastructure across Chinese provinces and tier markets.

For founders and operators, China Life Insurance is best approached as a late-stage institutional partner for established Chinese healthcare services and digital health platforms ready to scale within China, rather than as a venture investor for early-stage companies. The right profile includes operators with proven revenue, regulatory relationships, and clear alignment with national healthcare priorities such as elder care, primary care expansion, and chronic disease management. Engagement typically runs through investment banks, asset managers, and government-affiliated channels. Founders should expect institutional governance, long horizons, and rigorous regulatory and policy diligence.